Watchman FLX Left Atrial Appendage Closure Device Post Approval Study
WATCHMAN FLX is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy.
Study Type
OBSERVATIONAL
Enrollment
300
Patients who are receiving the Watchman FLX device
Aarhus University Hospital
Aarhus, Denmark
Hospices Civils de Lyon
Lyon, France
Elisabeth Krankenhaus
Essen, Germany
procedural success
Time frame: 7 days post-implant
incidence of stroke, leak, thrombus and death
Time frame: 1 year
procedural complications
Time frame: 7-days post implant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cardio Vasculares Centrum Sankt Katharinen
Frankfurt, Germany
Cardioangiologisches Centrum Bethanien
Frankfurt, Germany
Cardiologicum Hamburg
Hamburg, Germany
Uni Jena
Jena, Germany
Herzzentrum Universität Leipzig
Leipzig, Germany
Beaumont Hospital
Dublin, Ireland
Ospedale San Raffaele
Milan, Italy
...and 7 more locations